A Study of MET233 in Combination With MET097
Phase 1/2
132
about 11 months
18–75
1 site in CA
About this study
Researchers are testing a treatment combination (MET233 and MET097) for people with obesity or overweight, possibly including those with diabetes. The trial will examine the safety and how well the medication works in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take MET233
- 2.Take MET233 and MET097
- 3.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part A: Occurrence of treatment-emergent adverse events (TEAEs), Part B: Occurrence of treatment-emergent adverse events (TEAEs), Part C: Occurrence of treatment-emergent adverse events (TEAEs)
Secondary: Part A: Area under the concentration versus time curve (AUC), Part A: Maximum observed concentration (Cmax), Part A: Percent change from baseline in body weight, Part A: Time to maximum observed concentration (Tmax), Part B: Area under the concentration versus time curve (AUC), Part B: Maximum observed concentration (Cmax), Part B: Percent change from baseline in body weight, Part B: Time to maximum observed concentration (Tmax)
Endocrinology